Fosfomycin for ESBL E. coli UTI
For uncomplicated cystitis caused by ESBL-producing E. coli, use fosfomycin 3 grams as a single oral dose; for complicated UTIs or pyelonephritis caused by ESBL organisms, fosfomycin should NOT be used as monotherapy due to insufficient efficacy data.
Uncomplicated Cystitis (Lower UTI)
For simple bladder infections in otherwise healthy women:
- Dosing: Fosfomycin 3 grams orally as a single dose 1, 2
- Efficacy: Cure rates of 83-91% for uncomplicated cystitis 1
- ESBL coverage: Fosfomycin maintains excellent activity against ESBL-producing E. coli, with 96.7-97.2% susceptibility rates 3, 4
The single-dose regimen is FDA-approved and guideline-recommended specifically for acute uncomplicated cystitis 2. This is the only scenario where standard fosfomycin dosing should be used for ESBL infections.
Complicated UTIs (cUTI)
Critical caveat: Multiple guidelines explicitly state that oral fosfomycin should be avoided for complicated UTIs and pyelonephritis due to insufficient efficacy data 5.
However, if you have no other oral options (patient cannot tolerate alternatives, documented resistance to all other agents, or failed prior therapy):
Off-Label Multi-Dose Regimen:
- Dosing: 3 grams orally every 48-72 hours for 3 total doses 6, 7, 8
- Duration: Typically 5-7 days total
- Evidence quality: Limited to observational studies only
- Outcomes: Clinical cure rates of 62-77% for complicated lower UTI 8, with microbiological cure around 50% 7, 9
When to Consider Multi-Dose Oral Fosfomycin:
- Patient has failed standard therapy
- ESBL organism resistant to fluoroquinolones and TMP-SMX
- Patient cannot tolerate or access IV therapy
- Complicated lower UTI only (not pyelonephritis)
- Patient has 0-2 complicating factors 7
Pyelonephritis (Upper UTI)
Do NOT use oral fosfomycin for pyelonephritis 5. The EAU guidelines explicitly state that "oral fosfomycin should be avoided as there are insufficient data regarding their efficacy" for uncomplicated pyelonephritis 5.
For ESBL pyelonephritis requiring oral therapy:
- Use oral fluoroquinolones (if susceptible and local resistance <10%)
- Consider oral cephalosporins (cefpodoxime 200 mg BID or ceftibuten 400 mg daily) with initial IV ceftriaxone dose 5
- If no oral options exist, hospitalize for IV therapy
IV Fosfomycin Option:
If IV fosfomycin is available (not standard in US):
- Dosing: 6 grams IV every 8 hours for 7 days (14 days if bacteremic) 6
- Evidence: Superior to piperacillin-tazobactam for complicated upper UTI with ESBL organisms in the ZEUS trial 6
Key Clinical Pearls
Absorption considerations:
- Bioavailability is only 18-37% orally 2, 10
- Food reduces absorption by 20-30% but doesn't affect total urinary excretion 2
- Can be taken with or without food 2
- Avoid metoclopramide co-administration (reduces fosfomycin levels) 2
Resistance patterns:
- ESBL E. coli: 95-97% susceptible 3, 4
- ESBL Klebsiella: Lower susceptibility, less reliable 3
- Other Enterobacterales: Variable, often resistant 4
Common pitfall: Using single-dose fosfomycin for complicated UTI or pyelonephritis. This will fail. Either use the multi-dose regimen for complicated lower UTI only, or choose a different agent entirely.
Safety: Well-tolerated with 5.6% adverse events, primarily mild diarrhea 8. No serious drug-related adverse events in clinical studies.